AstraZeneca PLC
AZN
$189.90
-$2.60-1.35%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 55.07% | 77.26% | 27.14% | 33.82% | 56.25% |
| Total Depreciation and Amortization | 85.71% | -14.75% | 8.60% | 2.31% | -46.02% |
| Total Amortization of Deferred Charges | 18.00% | -- | -- | -- | -28.57% |
| Total Other Non-Cash Items | -120.39% | 126.04% | -1,450.00% | 87.63% | 623.73% |
| Change in Net Operating Assets | -243.14% | 1,936.59% | -167.44% | 6.37% | -333.33% |
| Cash from Operations | -19.44% | 51.76% | 9.76% | 49.36% | 22.14% |
| Capital Expenditure | -46.33% | -64.51% | -72.51% | -2.88% | -34.86% |
| Sale of Property, Plant, and Equipment | 50.00% | -- | -- | -98.11% | 100.00% |
| Cash Acquisitions | 0.36% | -24.71% | 88.38% | 61.81% | -26.85% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.35% | -18.35% | -517.10% | 57.95% | 40.36% |
| Cash from Investing | -22.44% | -32.17% | 26.60% | 48.07% | -9.66% |
| Total Debt Issued | -76.92% | 15.18% | -57.12% | -81.61% | -1,221.57% |
| Total Debt Repaid | -1,671.43% | 95.54% | 95.76% | -4.94% | 67.04% |
| Issuance of Common Stock | 0.00% | 25.00% | -20.00% | 33.33% | 9.52% |
| Repurchase of Common Stock | -- | 76.54% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -2.22% | 41.18% | -10.35% | -50.00% |
| Other Financing Activities | -988.89% | -112.50% | -- | 112.37% | -- |
| Cash from Financing | -389.12% | 49.82% | 142.39% | -233.48% | -130.58% |
| Foreign Exchange rate Adjustments | 106.56% | -160.00% | 583.33% | 154.35% | -1,116.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -339.64% | 146.74% | 279.80% | -110.80% | -2.36% |